Thursday, May 2, 2013

• OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013CNW Group( (Thu 4:01PM EDT)
• OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013PR Newswire( (Thu 4:00PM EDT)
• Teva Reports First Quarter 2013 ResultsBusiness Wire( (Thu 7:00AM EDT)

Wednesday, May 1, 2013

• OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic CancerPR Newswire( (Wed, May 1)
• OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic CancerCNW Group( (Wed, May 1)

Tuesday, April 30, 2013

• FDA Approves Over-The-Counter Availability of Plan B One-Step® (levonorgestrel) tablet 1.5 mg for Consumers 15 and OverBusiness Wire( (Tue, Apr 30)
• OncoGenex Announces that the Borealis-2™ Clinical Trial of OGX-427 in Previously Treated Metastatic Bladder Cancer is now Open for EnrollmentCNW Group( (Tue, Apr 30)
• OncoGenex Announces that the Borealis-2™ Clinical Trial of OGX-427 in Previously Treated Metastatic Bladder Cancer is now Open for EnrollmentPR Newswire( (Tue, Apr 30)

Monday, April 29, 2013

• Teva Expands Management Team with Appointment of Paul J. Sekhri as Group Executive Vice President, Global Business Development and Chief Strategy OfficerBusiness Wire( (Mon, Apr 29)

Wednesday, April 24, 2013

• Teva Establishes Global Specialty Medicines GroupBusiness Wire( (Wed, Apr 24)

Tuesday, April 23, 2013

• Teva and Xenon Announce FDA Orphan Drug Designation for Pain Drug XEN402Business Wire( (Tue, Apr 23)
• More Than Half of Nasal Allergy Sufferers Experience Sleep Issues, Yet Many Fail to Adequately Prepare in Advance of Peak Allergy SeasonsPR Newswire( (Tue, Apr 23)

Wednesday, April 17, 2013

• Teva Presented New Data from Phase III Clinical Trial of Milprosa™ (Progesterone) Vaginal Ring at the 61st Annual Meeting of the Pacific Coast Reproductive SocietyBusiness Wire( (Wed, Apr 17)